Medifast Earnings Call: Productivity Rises Amid Sharp Decline

Medifast ((MED)) has held its Q1 earnings call. Read on for the main highlights of the call.

Medifast’s latest earnings call struck a cautious but constructive tone as management pointed to rising coach productivity, early signs of revenue stabilization, and a strong cash position, even as headline metrics remained weak. The company stressed that its turnaround hinges on executing a new metabolic‑health product strategy to offset steep declines in coaches, margins, and profitability.

Coach Productivity Jumps Despite Smaller Field

Average revenue per active earning coach climbed to $5,432, up 19.2% year over year and 16% sequentially, marking the strongest productivity gains in years. Management called this the second straight quarter of year‑over‑year improvement and framed coach productivity as a key leading indicator for future revenue and channel health.

First Sequential Revenue Uptick in Three Years

Revenue in Q1 2026 came in at $76.0 million, edging above roughly $75 million in Q4 2025 and ending a three‑year stretch of quarter‑over‑quarter declines. Executives characterized this modest increase as early evidence of stabilization following a prolonged downturn, while cautioning that broader recovery will take time.

Balance Sheet Strength Buys Turnaround Runway

Medifast closed the quarter with $168.9 million in cash, cash equivalents, and investments and reported no debt on its balance sheet. Working capital of $160.4 million gives the company financial flexibility to fund product launches and restructuring efforts while absorbing continued near‑term operating losses.

Aggressive Cost Cuts Target Path Back to Profit

SG&A expenses dropped 35.6% year over year to $55.1 million, helped by lower coach compensation, reduced company‑led marketing, and a gain from a distribution center sale. Management expects its recent realignment to deliver more than $30 million in ongoing savings, which it views as critical to restoring profitability as volumes rebuild.

Metabolic Science and New Product System Take Center Stage

The company highlighted clinical data underpinning its metabolic synchronization approach, citing meaningful visceral fat reduction with high lean‑mass preservation. A new proprietary metabolic system is slated for launch to coaches later this year, with early pilot feedback described as encouraging and central to Medifast’s repositioning around broader metabolic health.

Field Engagement and Referral Engine Strengthen

Management reported improving field engagement, including more coaches reaching higher ranks and an uptick in coach‑led meetings and events. March saw a record share of new clients from referrals, and coaches in the referral program generated roughly twice the client acquisition of nonparticipants, suggesting momentum in relationship‑driven growth.

Revenue Still Down Sharply Year Over Year

Despite sequential stabilization, Q1 2026 revenue fell 34.3% versus the prior‑year quarter, underscoring the depth of the downturn. The company attributed the decline largely to a smaller active coach base, which continues to weigh heavily on top‑line performance.

Coach Headcount Erosion Remains a Core Risk

Active earning coaches dropped to about 14,000, a steep 44.9% year‑over‑year contraction in Medifast’s main distribution channel. Management did not offer a timeline for rebuilding absolute coach numbers, emphasizing instead productivity gains and engagement while acknowledging this structural pressure.

Margins Compress as Volumes Fall

Gross profit slid 38.6% year over year to $51.8 million, and gross margin narrowed to 68.1% from 72.8%. The margin erosion reflects weaker fixed‑cost leverage on lower sales volumes, a dynamic the company aims to counter through higher‑value offerings and future scale.

Net Loss Widens and Losses Expected to Persist

Medifast posted a Q1 2026 net loss of $2.1 million, or $0.19 per share, versus a $0.8 million loss a year earlier. Guidance for both Q2 and full‑year 2026 points to continued red ink, signaling that the turnaround remains in an investment phase and that earnings recovery is not imminent.

GLP‑1 Drugs Disrupt Traditional Weight‑Loss Model

Management again flagged the rapid adoption of GLP‑1 medications as a major headwind, contributing to the shrinking coach base and reshaping the weight‑management market. The company sees its future in broader metabolic health support rather than traditional dieting alone, but the competitive landscape remains challenging.

Execution Risk Around New Product Launch

The path back to improved profitability is tied closely to the rollout and uptake of the new metabolic system planned for later this year. Executives acknowledged that delays or weaker‑than‑expected adoption could push out their margin and earnings recovery timeline, highlighting execution risk at a critical strategic pivot.

Guidance: Losses to Continue as Turnaround Builds

Medifast reaffirmed 2026 revenue guidance of $270–$300 million and a full‑year loss per share range of $1.05–$2.75, alongside Q2 revenue guidance of $60–$80 million with a projected loss per share of $0.50–$1.00. The company anticipates ongoing coach productivity gains, a step‑up toward profitability beginning in Q4 2026 as the new product launches, and year‑end working capital above $140 million.

Management’s message blended realism about current pressures with confidence in its strategic reset around metabolic health and coach productivity. For investors, Medifast’s strong liquidity and early operational wins are positives, but sustained losses, coach attrition, and heavy reliance on a successful product launch keep risk high and the turnaround story still in its early innings.